Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC raised its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 24.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 263,900 shares of the company’s stock after acquiring an additional 51,300 shares during the period. Renaissance Technologies LLC owned approximately 0.47% of Black Diamond Therapeutics worth $1,230,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bellevue Group AG lifted its position in Black Diamond Therapeutics by 4.9% in the fourth quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock valued at $23,986,000 after purchasing an additional 400,000 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Black Diamond Therapeutics during the 1st quarter valued at approximately $82,000. Acadian Asset Management LLC boosted its position in Black Diamond Therapeutics by 13.8% during the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after purchasing an additional 20,616 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Black Diamond Therapeutics in the 2nd quarter valued at about $108,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Black Diamond Therapeutics in the second quarter valued at approximately $508,000. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BDTX. Raymond James started coverage on shares of Black Diamond Therapeutics in a research note on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 target price for the company. Wedbush reissued an “outperform” rating and set a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, September 10th. Piper Sandler lifted their target price on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Tuesday, September 24th.

Black Diamond Therapeutics Price Performance

BDTX opened at $3.75 on Friday. Black Diamond Therapeutics, Inc. has a 12-month low of $1.62 and a 12-month high of $7.66. The firm’s fifty day moving average price is $5.32 and its 200 day moving average price is $5.34. The stock has a market capitalization of $210.95 million, a PE ratio of -2.26 and a beta of 2.47.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts forecast that Black Diamond Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.